Speaking of Urology: 2023 AUA Highlights

In this episode of Speaking of Urology^®, Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 American Urological Association Annual meeting, which was held April 28-May 1 in Chicago, Illinois. Weiner is a urologic oncology fellow at the University of California, Los Angeles, and Talwar is a urologic oncology fellow at Vanderbilt University in Nashville, Tennessee.

This recap was originally presented by Dr. Weiner and Dr. Talwar during a live Twitter Spaces event held by Urology Times. In the discussion, Weiner and Talwar touch on the followed abstracts:

• LBA02-09: EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
• LBA02-11: Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)
• LBA02-03 First results from SunRISE-1 in patients with BCG unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, tar-200, or cetrelimab alone
• LBA02-08 Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CHeckMATE 274 trial
• LBA03-01: 89Zr-DFO-girentuximab for PET/CT Imaging of Indeterminate Renal Masses - Results from Phase 3 ZIRCON Study

Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.